Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma

• Status: Completed
• Trial end date: 2019-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is

1. to determine the recommended dose of everolimus for a subsequent Phase II trial

2. to determine the efficacy of everolimus plus DHAP

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cologne
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• relapsed or refractory Hodgkin Lymphoma

• age 18-60

• histology confirmed relapse

Exclusion Criteria:

• previous therapy with mTOR inhibitor

• current CNS involvement

• other primary malignant disease within the last 3 years